QBiotics to present at BIO 2026 International Convention and participate in MTEC Annual Meeting
BRISBANE, 15 June 2026
QBiotics Group Limited (QBiotics) is pleased to announce it will present at the BIO 2026 International Convention and participate in the 10th Annual Medical Technology Enterprise Consortium (MTEC) Membership Meeting, both being held in the USA during June 2026.
BIO 2026 will be held in San Diego from 22-25 June. Interim CEO and Managing Director, Ebru Davidson will present at this leading global biotechnology and life sciences conference, profiling QBiotics’ oncology and wound healing programmes.
The MTEC Membership Meeting will be held in Washington DC from 16-17 June, where QBiotics will participate as part of the Queensland Government-led delegation. The Company will present a poster on its wound healing candidate, EBC-1013, and be featured in the Queensland Defense health magazine “Advancing Health Innovations.”
Ebru Davidson commented, “Engaging at premier conferences like the BIO International Convention, alongside initiatives such as the MTEC Membership Meeting, is integral to strengthening our relationships with partners and investors. We look forward to highlighting our oncology program, as well as providing further detail on EBC‑1013 and its encouraging early promise in wound healing.”
— ends —
FURTHER INFORMATION
EBRU DAVIDSON, INTERIM CEO & MANAGING DIRECTOR
communications@qbiotics.com
or
MEDIA ENQUIRIES
JANE LOWE, IR DEPARTMENT
jane.lowe@irdepartment.com.au or +61 411 117 774
NOTES FOR EDITORS
ABOUT QBIOTICS
QBiotics Group Limited (QBiotics) is an Australian public unlisted biotechnology company, advancing two clinical-stage, differentiated, small molecule programmes derived from our epoxytigliane platform.
QBiotics’ lead intratumoural oncology asset, tigilanol tiglate, is demonstrating strong efficacy and safety in human clinical Phase II studies. In a Phase II soft tissue sarcoma study the drug delivered an injected tumour Objective Response Rate (ORR) of 80%, with no serious Adverse Events, and translational research validating immunological responses. A Phase II study in head & neck cancer is soon to be reported and impressive safety and efficacy outcomes have been achieved in a range of other tumour types under Compassionate Use. No Maximum Tolerated Dose (MTD) was declared in a Phase I/IIa safety study and efficacy reported for nine different tumour types.
QBiotics’ second programme is a topically applied regenerative wound therapy EBC-1013 that accelerates wound infill and closure, minimises scarring, and provides local antimicrobial activity. This drug candidate has demonstrated impressive safety and efficacy against chronic and acute wounds and burns in veterinary studies. It is currently in a human clinical Phase I/IIa study treating Venous Leg Ulcers.
Patent coverage for tigilanol tiglate and EBC-1013 is broad and Chemistry, Manufacturing and Controls (CMC) is mature, with commercial supply of the drug secured for both programmes.
QBiotics employs a capital-efficient model that integrates its EcoLogic™ discovery technology with phenotypic screening and early validation in veterinary disease models. This approach enables rapid identification of biologically active molecules, early demonstration of efficacy and safety in complex disease settings, and meaningful de-risking prior to human clinical development. Product development is led by an experienced team and complemented by internationally recognised Key Opinion Leaders on our Clinical and Scientific Advisory Boards, who bring deep expertise in oncology, wound healing, antimicrobials, and translational drug development.
QBiotics’ business strategy is to advance therapeutic programmes with the potential to address multiple high-value indications through to Phase II proof-of-concept in human clinical studies, and then pursue strategic partnering to accelerate late-stage development and commercialisation.
For more, head to: QBiotics.com or LinkedIn